Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)

  1. San-Miguel, J.
  2. Usmani, S.Z.
  3. Mateos, M.-V.
  4. van de Donk, N.W.C.J.
  5. Kaufman, J.L.
  6. Moreau, P.
  7. Oriol, A.
  8. Plesner, T.
  9. Benboubker, L.
  10. Liu, K.
  11. Hellemans, P.
  12. Masterson, T.
  13. Clemens, P.L.
  14. Luo, M.
  15. Farnsworth, A.
  16. Nahi, H.
  17. Chari, A.
Revue:
Haematologica

ISSN: 1592-8721

Année de publication: 2021

Volumen: 106

Número: 6

Pages: 1725-1732

Type: Article

DOI: 10.3324/HAEMATOL.2019.243790 GOOGLE SCHOLAR lock_openAccès ouvert editor